Table 1.
Main progresses of Car-T cell therapy
| Time | Researcher/Product | Event | Institutec |
|---|---|---|---|
| 1993 | Zelig Eshhar | First-generation CARs (CD3ζ-based) | NCI, Rosenberg lab |
| 2002 | Michael Sadelain | Second-generation CARs (CD28-based) | Memorial Sloan Kettering Cancer Center (MSKCC) |
| 2004 | Dario Campana | Second-generation CARs (4-1BB-based) | National University of Singapore (NUS) |
| 2010 | Mcichel Sadelain | Third-generation CARs | Memorial Sloan Kettering Cancer Center (MSKCC) |
| 2011 | Carl June | First report of CD19 CAR therapy in CLL | University of Pennsylvania |
| 2013 | Carl June | First report of CD19 CAR therapy in ALL | University of Pennsylvania |
| 2013 | Hinrich Abken | Fourth-generation CARs (TRUCK) | University of Cologne |
| 2017 | Kymriah, Yescarta | FDA approval of CD19 CAR therapy | Novartis and Gilead (Kite) |